Skip to main
VRDN
VRDN logo

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics Inc. demonstrates a promising outlook due to its product candidate Veligrotug, which has shown potential to match and even surpass the benefits of existing therapies for thyroid eye disease (TED), specifically in proptosis and diplopia reduction. The introduction of the subcutaneous formulation, VRDN-003, is expected to strengthen the company’s market position by improving treatment accessibility and patient quality of life, thus enhancing market share. Moreover, the company’s second-mover advantage allows it to address the shortcomings of current therapies, positioning Viridian for significant advancements in autoimmune treatment and future commercial success.

Bears say

The analysis indicates a negative outlook for Viridian Therapeutics due to several fundamental concerns, including potential vulnerabilities in intellectual property protection that could jeopardize its competitive positioning in the market. Additionally, risks associated with the manufacturing process and the pressures of an accelerated Biologics License Application (BLA) timeline raise doubts about management's execution capabilities, which could negatively impact future commercialization efforts. Furthermore, the company faces substantial competition from well-capitalized rivals with established products, which may hinder Viridian's market share and pricing power, compounded by the high treatment burden associated with existing therapies like Tepezza, potentially limiting patient adoption.

Viridian Therapeutics (VRDN) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 9 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.